Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 4;15(1):e33339.
doi: 10.7759/cureus.33339. eCollection 2023 Jan.

A Comparative Study of Sublingual Misoprostol Versus Intramuscular Oxytocin in the Active Management of Third Stage of Labor

Affiliations

A Comparative Study of Sublingual Misoprostol Versus Intramuscular Oxytocin in the Active Management of Third Stage of Labor

Shweta Mishra et al. Cureus. .

Abstract

Objective Misoprostol has attracted low-income low-resource countries for the active management of the third stage of labor. The objective of this study was to compare the efficacy of sublingual misoprostol and intramuscular oxytocin in the active management of the third stage of labor. Study design This was a prospective randomized controlled trial in which a total of 407 healthy pregnant women having singleton pregnancy, cephalic presentation, and normal vaginal delivery were divided into two groups. In the first group (n=203), women received 600 µg misoprostol tablet sublingually, and in the second group (n=204), women received 10 IU of intramuscular oxytocin, within 1 minute of the delivery of the baby during the third stage of labor. Three patients from the first group and four patients from the second group were excluded from the analysis due to traumatic postpartum hemorrhage (PPH). The primary outcome was an incidence of PPH. Secondary outcomes were the duration of the third stage of labor, amount of blood loss, fall in hemoglobin concentration after 48 hours of delivery, need for additional uterotonics, and side effects of the drugs. Data were compared using the chi-square and independent samples t-test. Results The incidence of PPH was 6.5% in the misoprostol group as compared to 2% in the oxytocin group (p=0.026). The misoprostol group also had significantly higher blood loss (293.75±125.8 mL) and a greater fall in hemoglobin level (0.58±0.25 g/dL) as compared to that in the oxytocin group (226.13±98.44 mL and 0.45±0.20 g/dL) (p<0.001). The mean duration of the third stage of labor was significantly higher in the misoprostol group (5.31±2.1 min) as compared to that in the oxytocin group (3.65±1.75 min) (p<0.001). The additional need for uterotonics was recorded in 15% of the study participants in the misoprostol group as compared to 8% in the oxytocin group (p=0.028). The incidence of side effects such as shivering and fever was significantly higher in the misoprostol group as compared to the oxytocin group. No significant difference between the two groups was observed concerning the incidence of nausea, vomiting, diarrhea, and headache. Conclusion Intramuscular oxytocin is a safe and useful alternative to sublingual misoprostol in facilitating the third stage of labor with minimal blood loss, fewer incidences of hemorrhage, and fewer adverse effects.

Keywords: oxytocin; postpartum hemorrhage; sublingual misoprostol; third stage of labor; uterotonics.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. CONSORT flow diagram depicting patient enrollment
PPH, postpartum hemorrhage; CONSORT, Consolidated Standards of Reporting Trials
Figure 2
Figure 2. Comparison of the side effects of two drugs used in the study

Similar articles

Cited by

References

    1. World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. [ Oct; 2022 ]. 2012. https://apps.who.int/iris/bitstream/handle/10665/75411/9789241548502_eng... https://apps.who.int/iris/bitstream/handle/10665/75411/9789241548502_eng... - PubMed
    1. Prevention of postpartum hemorrhage in low-resource settings: current perspectives. Prata N, Bell S, Weidert K. Int J Womens Health. 2013;5:737–752. - PMC - PubMed
    1. Registration, procurement, distribution, and use of misoprostol in Uganda: an interview-based observational study. Atukunda EC, Brhlikova P, Agaba AG, Pollock AM. Lancet. 2013;382:10. - PubMed
    1. Management of third stage of labor with misoprostol: a comparison of three routes of administration. Bajwa SK, Bajwa SJ, Kaur H, Goraya SP, Singh A, Kaurishar H. Perspect Clin Res. 2012;3:102–108. - PMC - PubMed
    1. New and underutilized technologies to reduce maternal mortality: call to action from a Bellagio workshop. Tsu VD, Shane B. Int J Gynaecol Obstet. 2004;85 Suppl 1:0–93. - PubMed

LinkOut - more resources